Immune correlates of HIV control

Current Medicinal Chemistry

Volumn 18, Issue 26, 2011, Pages 3963-3970

  Prado, J G ^a   Carrillo, J ^a   Blanco Heredia, J ^b   Brander, C ^a,c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

B cells; Control; Correlates; HIV; Immunity; T cells; Vaccine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; GLYCOPROTEIN GP 140; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RITUXIMAB; T LYMPHOCYTE RECEPTOR;

B LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; GENETIC MARKER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION CONTROL; INFECTION SENSITIVITY; LYMPHOMA; MEMORY T LYMPHOCYTE; NONHUMAN; OPPORTUNISTIC INFECTION; REVIEW; VIREMIA; VIRUS REPLICATION;

AIDS VACCINES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, HUMORAL;

EID: 80052186931     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796957202     Document Type: Review

References (122)

1. Sun, J. C.; Beilke, J. N.; Lanier, L. L., Adaptive immune features of natural killer cells. Nature 2009, 457(7229), 557-61.
2. Zuniga, R.; Lucchetti, A.; Galvan, P.; Sanchez, S.; Sanchez, C.; Hernandez, A.; Sanchez, H.; Frahm, N.; Linde, C. H.; Hewitt, H. S.; Hildebrand, W.; Altfeld, M.; Allen, T. M.; Walker, B. D.; Korber, B. T.; Leitner, T.; Sanchez, J.; Brander, C., Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006, 80(6), 3122-5. (Pubitemid 43346412)
3. Koup, R. A.; Safrit, J. T.; Cao, Y.; Andrews, C. A.; McLeod, G.; Borkowsky, W.; Farthing, C.; Ho, D. D., Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68(7), 4650-5. (Pubitemid 24183063)
4. Schmitz, J. E.; Kuroda, M. J.; Santra, S.; Sasseville, V. G.; Simon, M. A.; Lifton, M. A.; Racz, P.; Tenner-Racz, K.; Dalesandro, M.; Scallon, B. J.; Ghrayeb, J.; Forman, M. A.; Montefiori, D. C.; Rieber, E. P.; Letvin, N. L.; Reimann, K. A., Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283(5403), 857-60.
5. Kaslow, R. A.; Carrington, M.; Apple, R.; Park, L.; Munoz, A.; Saah, A. J.; Goedert, J. J.; Winkler, C.; O'Brien, S. J.; Rinaldo, C.; Detels, R.; Blattner, W.; Phair, J.; Erlich, H.; Mann, D. L., Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2(4), 405-11. (Pubitemid 26193012)
6. Frahm, N.; Adams, S.; Kiepiela, P.; Linde, C. H.; Hewitt, H. S.; Lichterfeld, M.; Sango, K.; Brown, N. V.; Pae, E.; Wurcel, A. G.; Altfeld, M.; Feeney, M. E.; Allen, T. M.; Roach, T.; St John, M. A.; Daar, E. S.; Rosenberg, E.; Korber, B.; Marincola, F.; Walker, B. D.; Goulder, P. J.; Brander, C., HLAB63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol 2005, 79(16), 10218-25. (Pubitemid 41098563)
7. Fellay, J.; Shianna, K. V.; Ge, D.; Colombo, S.; Ledergerber, B.; Weale, M.; Zhang, K.; Gumbs, C.; Castagna, A.; Cossarizza, A.; Cozzi-Lepri, A.; De Luca, A.; Easterbrook, P.; Francioli, P.; Mallal, S.; Martinez-Picado, J.; Miro, J. M.; Obel, N.; Smith, J. P.; Wyniger, J.; Descombes, P.; Antonarakis, S. E.; Letvin, N. L.; McMichael, A. J.; Haynes, B. F.; Telenti, A.; Goldstein, D. B., A whole-genome association study of major determinants for host control of HIV-1. Science 2007, 317(5840), 944-7. (Pubitemid 47301321)
8. Carrington, M.; Martin, M. P.; van Bergen, J., KIR-HLA intercourse in HIV disease. Trends Microbiol 2008, 16(12), 620-7.
9. Buchbinder, S. P.; Mehrotra, D. V.; Duerr, A.; Fitzgerald, D. W.; Mogg, R.; Li, D.; Gilbert, P. B.; Lama, J. R.; Marmor, M.; Del Rio, C.; McElrath, M. J.; Casimiro, D. R.; Gottesdiener, K. M.; Chodakewitz, J. A.; Corey, L.; Robertson, M. N., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 2008, 372(9653), 1881-93.
10. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E.; Benenson, M.; Gurunathan, S.; Tartaglia, J.; McNeil, J. G.; Francis, D. P.; Stablein, D.; Birx, D. L.; Chunsuttiwat, S.; Khamboonruang, C.; Thongcharoen, P.; Robb, M. L.; Michael, N. L.; Kunasol, P.; Kim, J. H., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23), 2209-20.
11. Rolland, M.; Tovanabutra, S.; deCamp, A.C.; Frahm, N.; Gilbert, P.B.; Sanders-Buell, E.; Heath, L.; Magaret, C.A.; Bose, M.; Bradfield, A.; O'Sullivan, A.; Crossler, J.; Jones, T.; Nau, M.; Wong, K.; Zhao, H.; Raugi, D.N.; Sorensen, S.; Stoddard, J.N.; Maust, B.S.; Deng, W.; Hural, J.; Dubey, S.; Michael, N.L.; Shiver, J.; Corey, L.; Li, F.; Self, S.G.; Kim, J.; Buchbinder, S.; Casimiro, D.R.; Robertson, M.N.; Duerr, A.; McElrath, M.J.; McCutchan, F.E.; Mullins, J.I. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011, 17(3), 366-71. Epub 2011 Feb 27.
12. Walker, B. D.; Chakrabarti, S.; Moss, B.; Paradis, T. J.; Flynn, T.; Durno, A. G.; Blumberg, R. S.; Kaplan, J. C.; Hirsch, M. S.; Schooley, R. T., HIVspecific cytotoxic T lymphocytes in seropositive individuals. Nature 1987, 328(6128), 345-8. (Pubitemid 17097655)
13. Llano, A.; Frahm, N.; Brander, C., How to Optimally Define Optimal Cytotoxic T Lymphocyte Epitopes in HIV Infection? In HIV Molecular immunology database, B. Korber, C. B., B. Walker, R. Koup, J. Moore, B. Haynes, G. Meyers, Ed. Los Alamos National Laboratory: Theoretical Biology and Biophysics: Los Alamos, NM, USA, 2009.
14. Frahm, N.; Korber, B. T.; Adams, C. M.; Szinger, J. J.; Draenert, R.; Addo, M. M.; Feeney, M. E.; Yusim, K.; Sango, K.; Brown, N. V.; SenGupta, D.; Piechocka-Trocha, A.; Simonis, T.; Marincola, F. M.; Wurcel, A. G.; Stone, D. R.; Russell, C. J.; Adolf, P.; Cohen, D.; Roach, T.; StJohn, A.; Khatri, A.; Davis, K.; Mullins, J.; Goulder, P. J.; Walker, B. D.; Brander, C., Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004, 78(5), 2187-200. (Pubitemid 38228912)
15. Kiepiela, P.; Leslie, A. J.; Honeyborne, I.; Ramduth, D.; Thobakgale, C.; Chetty, S.; Rathnavalu, P.; Moore, C.; Pfafferott, K. J.; Hilton, L.; Zimbwa, P.; Moore, S.; Allen, T.; Brander, C.; Addo, M. M.; Altfeld, M.; James, I.; Mallal, S.; Bunce, M.; Barber, L. D.; Szinger, J.; Day, C.; Klenerman, P.; Mullins, J.; Korber, B.; Coovadia, H. M.; Walker, B. D.; Goulder, P. J., Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004, 432(7018), 769-75.
16. Bihl, F.; Frahm, N.; Di Giammarino, L.; Sidney, J.; John, M.; Yusim, K.; Woodberry, T.; Sango, K.; Hewitt, H. S.; Henry, L.; Linde, C. H.; Chisholm, J. V., 3rd; Zaman, T. M.; Pae, E.; Mallal, S.; Walker, B. D.; Sette, A.; Korber, B. T.; Heckerman, D.; Brander, C., Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006, 176(7), 4094-101. (Pubitemid 44264388)
17. Miura, T.; Brockman, M. A.; Schneidewind, A.; Lobritz, M.; Pereyra, F.; Rathod, A.; Block, B. L.; Brumme, Z. L.; Brumme, C. J.; Baker, B.; Rothchild, A. C.; Li, B.; Trocha, A.; Cutrell, E.; Frahm, N.; Brander, C.; Toth, I.; Arts, E. J.; Allen, T. M.; Walker, B. D., HLA-B57/B5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic Tlymphocyte [corrected] recognition. J Virol 2009, 83(6), 2743-55.
18. Saez-Cirion, A.; Lacabaratz, C.; Lambotte, O.; Versmisse, P.; Urrutia, A.; Boufassa, F.; Barre-Sinoussi, F.; Delfraissy, J. F.; Sinet, M.; Pancino, G.; Venet, A., HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007, 104(16), 6776-81. (Pubitemid 47175577)
19. Betts, M. R.; Nason, M. C.; West, S. M.; De Rosa, S. C.; Migueles, S. A.; Abraham, J.; Lederman, M. M.; Benito, J. M.; Goepfert, P. A.; Connors, M.; Roederer, M.; Koup, R. A., HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(12), 4781-9. (Pubitemid 43882629)
20. Migueles, S. A.; Osborne, C. M.; Royce, C.; Compton, A. A.; Joshi, R. P.; Weeks, K. A.; Rood, J. E.; Berkley, A. M.; Sacha, J. B.; Cogliano-Shutta, N. A.; Lloyd, M.; Roby, G.; Kwan, R.; McLaughlin, M.; Stallings, S.; Rehm, C.; O'Shea, M. A.; Mican, J.; Packard, B. Z.; Komoriya, A.; Palmer, S.; Wiegand, A. P.; Maldarelli, F.; Coffin, J. M.; Mellors, J. W.; Hallahan, C. W.; Follman, D. A.; Connors, M., Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29(6), 1009-21.
21. Hansen, S. G.; Vieville, C.; Whizin, N.; Coyne-Johnson, L.; Siess, D. C.; Drummond, D. D.; Legasse, A. W.; Axthelm, M. K.; Oswald, K.; Trubey, C. M.; Piatak, M., Jr.; Lifson, J. D.; Nelson, J. A.; Jarvis, M. A.; Picker, L. J., Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15(3), 293-9.
22. Li, Q.; Skinner, P. J.; Ha, S. J.; Duan, L.; Mattila, T. L.; Hage, A.; White, C.; Barber, D. L.; O'Mara, L.; Southern, P. J.; Reilly, C. S.; Carlis, J. V.; Miller, C. J.; Ahmed, R.; Haase, A. T., Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009, 323(5922), 1726-9.
23. Bennett, M. S.; Ng, H. L.; Dagarag, M.; Ali, A.; Yang, O. O., Epitopedependent avidity thresholds for cytotoxic T-lymphocyte clearance of virusinfected cells. J Virol 2007, 81(10), 4973-80. (Pubitemid 46744409)
24. Almeida, J. R.; Sauce, D.; Price, D. A.; Papagno, L.; Shin, S. Y.; Moris, A.; Larsen, M.; Pancino, G.; Douek, D. C.; Autran, B.; Saez-Cirion, A.; Appay, V., Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 2009, 113(25), 6351-60.
25. Bennett, M. S.; Joseph, A.; Ng, H. L.; Goldstein, H.; Yang, O. O., Finetuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes. Aids 2010.
26. Berger, C.T.; Frahm, N.; Price, D.A.; Mothe, B.; Ghebremichael, M.; Hartman, K.L.; Henry, L.M.; Brenchley, J.M.; Ruff, L.E.; Venturi, V.; Pereyra, F.; Sidney, J.; Sette, A.; Douek, D.C.; Walker, B.D.; Kaufmann, D.E.; Brander, C. High functional avidity CTL responses to HLA-B-restricted Gag-derived epitopes associate with relative HIV control. J. Virol. 2011, [Epub ahead of print]
27. Almeida, J. R.; Price, D. A.; Papagno, L.; Arkoub, Z. A.; Sauce, D.; Bornstein, E.; Asher, T. E.; Samri, A.; Schnuriger, A.; Theodorou, I.; Costagliola, D.; Rouzioux, C.; Agut, H.; Marcelin, A. G.; Douek, D.; Autran, B.; Appay, V., Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007, 204(10), 2473-85. (Pubitemid 47529331)
28. Streeck, H.; Brumme, Z. L.; Anastario, M.; Cohen, K. W.; Jolin, J. S.; Meier, A.; Brumme, C. J.; Rosenberg, E. S.; Alter, G.; Allen, T. M.; Walker, B. D.; Altfeld, M., Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 2008, 5(5), e100.
29. Mothe, B.; Ibarrondo, J.; Llano, A.; Brander, C., Virological, immune and host genetics markers in the control of HIV infection. Dis Markers 2009, 27(3), 105-20.
30. Kosmrlj, A.; Read, E. L.; Qi, Y.; Allen, T. M.; Altfeld, M.; Deeks, S. G.; Pereyra, F.; Carrington, M.; Walker, B. D.; Chakraborty, A. K., Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 2010, 465(7296), 350-4.
31. Schneidewind, A.; Brockman, M. A.; Yang, R.; Adam, R. I.; Li, B.; Le Gall, S.; Rinaldo, C. R.; Craggs, S. L.; Allgaier, R. L.; Power, K. A.; Kuntzen, T.; Tung, C. S.; LaBute, M. X.; Mueller, S. M.; Harrer, T.; McMichael, A. J.; Goulder, P. J.; Aiken, C.; Brander, C.; Kelleher, A. D.; Allen, T. M., Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 2007, 81(22), 12382-93. (Pubitemid 350085852)
32. Prado, J. G.; Honeyborne, I.; Brierley, I.; Puertas, M. C.; Martinez-Picado, J.; Goulder, P. J., Functional consequences of human immunodeficiency virus escape from an HLA-B13-restricted CD8+ T-cell epitope in p1 Gag protein. J Virol 2009, 83(2), 1018-25.
33. Prado, J. G.; Prendergast, A.; Thobakgale, C.; Molina, C.; Tudor-Williams, G.; Ndung'u, T.; Walker, B. D.; Goulder, P., Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate. J Virol 2010, 84(1), 492-502.
34. Martinez-Picado, J.; Prado, J. G.; Fry, E. E.; Pfafferott, K.; Leslie, A.; Chetty, S.; Thobakgale, C.; Honeyborne, I.; Crawford, H.; Matthews, P.; Pillay, T.; Rousseau, C.; Mullins, J. I.; Brander, C.; Walker, B. D.; Stuart, D. I.; Kiepiela, P.; Goulder, P., Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006, 80(7), 3617-23.
35. Brumme, Z. L.; John, M.; Carlson, J. M.; Brumme, C. J.; Chan, D.; Brockman, M. A.; Swenson, L. C.; Tao, I.; Szeto, S.; Rosato, P.; Sela, J.; Kadie, C. M.; Frahm, N.; Brander, C.; Haas, D. W.; Riddler, S. A.; Haubrich, R.; Walker, B. D.; Harrigan, P. R.; Heckerman, D.; Mallal, S., HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 2009, 4(8), e6687.
36. Brumme, Z. L.; Tao, I.; Szeto, S.; Brumme, C. J.; Carlson, J. M.; Chan, D.; Kadie, C.; Frahm, N.; Brander, C.; Walker, B.; Heckerman, D.; Harrigan, P. R., Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. Aids 2008, 22(11), 1277-86.
37. Moore, C. B.; John, M.; James, I. R.; Christiansen, F. T.; Witt, C. S.; Mallal, S. A., Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296(5572), 1439-43. (Pubitemid 34553083)
38. Goulder, P. J.; Brander, C.; Tang, Y.; Tremblay, C.; Colbert, R. A.; Addo, M. M.; Rosenberg, E. S.; Nguyen, T.; Allen, R.; Trocha, A.; Altfeld, M.; He, S.; Bunce, M.; Funkhouser, R.; Pelton, S. I.; Burchett, S. K.; McIntosh, K.; Korber, B. T.; Walker, B. D., Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412(6844), 334-8. (Pubitemid 32694384)
39. Kawashima, Y.; Pfafferott, K.; Frater, J.; Matthews, P.; Payne, R.; Addo, M.; Gatanaga, H.; Fujiwara, M.; Hachiya, A.; Koizumi, H.; Kuse, N.; Oka, S.; Duda, A.; Prendergast, A.; Crawford, H.; Leslie, A.; Brumme, Z.; Brumme, C.; Allen, T.; Brander, C.; Kaslow, R.; Tang, J.; Hunter, E.; Allen, S.; Mulenga, J.; Branch, S.; Roach, T.; John, M.; Mallal, S.; Ogwu, A.; Shapiro, R.; Prado, J. G.; Fidler, S.; Weber, J.; Pybus, O. G.; Klenerman, P.; Ndung'u, T.; Phillips, R.; Heckerman, D.; Harrigan, P. R.; Walker, B. D.; Takiguchi, M.; Goulder, P., Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009.
40. Frahm, N.; Kiepiela, P.; Adams, S.; Linde, C. H.; Hewitt, H. S.; Sango, K.; Feeney, M. E.; Addo, M. M.; Lichterfeld, M.; Lahaie, M. P.; Pae, E.; Wurcel, A. G.; Roach, T.; St John, M. A.; Altfeld, M.; Marincola, F. M.; Moore, C.; Mallal, S.; Carrington, M.; Heckerman, D.; Allen, T. M.; Mullins, J. I.; Korber, B. T.; Goulder, P. J.; Walker, B. D.; Brander, C., Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006, 7(2), 173-8. (Pubitemid 43135883)
41. Trachtenberg, E.; Korber, B.; Sollars, C.; Kepler, T. B.; Hraber, P. T.; Hayes, E.; Funkhouser, R.; Fugate, M.; Theiler, J.; Hsu, Y. S.; Kunstman, K.; Wu, S.; Phair, J.; Erlich, H.; Wolinsky, S., Advantage of rare HLA supertype in HIV disease progression. Nat Med. 2003, 9, 928-93.
42. Koga, M.; Kawana-Tachikawa, A.; Heckerman, D.; Odawara, T.; Nakamura, H.; Koibuchi, T.; Fujii, T.; Miura, T.; Iwamoto, A., Changes in impact of HLA class I allele expression on HIV-1 plasma virus loads at a population level over time. Microbiol Immunol 2010, 54(4), 196-205.
43. Berger, C. T.; Carlson, J. M.; Brumme, C. J.; Hartman, K. L.; Brumme, Z. L.; Henry, L. M.; Rosato, P. C.; Piechocka-Trocha, A.; Brockman, M. A.; Harrigan, P. R.; Heckerman, D.; Kaufmann, D. E.; Brander, C., Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. J Exp Med 2010, 207(1), 61-75.
44. Bansal, A.; Carlson, J.; Yan, J.; Akinsiku, O. T.; Schaefer, M.; Sabbaj, S.; Bet, A.; Levy, D. N.; Heath, S.; Tang, J.; Kaslow, R. A.; Walker, B. D.; Ndung'u, T.; Goulder, P. J.; Heckerman, D.; Hunter, E.; Goepfert, P. A., CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. J Exp Med 2010, 207(1), 51-9.
45. Zolla-Pazner, S., Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004, 4(3), 199-210. (Pubitemid 38339086)
46. Baba, T. W.; Liska, V.; Hofmann-Lehmann, R.; Vlasak, J.; Xu, W.; Ayehunie, S.; Cavacini, L. A.; Posner, M. R.; Katinger, H.; Stiegler, G.; Bernacky, B. J.; Rizvi, T. A.; Schmidt, R.; Hill, L. R.; Keeling, M. E.; Lu, Y.; Wright, J. E.; Chou, T. C.; Ruprecht, R. M., Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000, 6(2), 200-6. (Pubitemid 30082366)
47. Hessell, A. J.; Poignard, P.; Hunter, M.; Hangartner, L.; Tehrani, D. M.; Bleeker, W. K.; Parren, P. W.; Marx, P. A.; Burton, D. R., Effective, lowtiter antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009, 15(8), 951-4.
48. Hessell, A. J.; Rakasz, E. G.; Poignard, P.; Hangartner, L.; Landucci, G.; Forthal, D. N.; Koff, W. C.; Watkins, D. I.; Burton, D. R., Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009, 5(5), e1000433.
49. Mascola, J. R.; Stiegler, G.; VanCott, T. C.; Katinger, H.; Carpenter, C. B.; Hanson, C. E.; Beary, H.; Hayes, D.; Frankel, S. S.; Birx, D. L.; Lewis, M. G., Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6(2), 207-10. (Pubitemid 30082367)
50. Shibata, R.; Igarashi, T.; Haigwood, N.; Buckler-White, A.; Ogert, R.; Ross, W.; Willey, R.; Cho, M. W.; Martin, M. A., Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999, 5(2), 204-10. (Pubitemid 29068528)
51. Mehandru, S.; Vcelar, B.; Wrin, T.; Stiegler, G.; Joos, B.; Mohri, H.; Boden, D.; Galovich, J.; Tenner-Racz, K.; Racz, P.; Carrington, M.; Petropoulos, C.; Katinger, H.; Markowitz, M., Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 2007, 81(20), 11016-31. (Pubitemid 47536075)
52. Trkola, A.; Kuster, H.; Rusert, P.; Joos, B.; Fischer, M.; Leemann, C.; Manrique, A.; Huber, M.; Rehr, M.; Oxenius, A.; Weber, R.; Stiegler, G.; Vcelar, B.; Katinger, H.; Aceto, L.; Gunthard, H. F., Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11(6), 615-22. (Pubitemid 40868301)
53. Kuan-Hsiang G. Huang, D. B., Aris Katzourakis, Emma C. Thomson, Sarah J. Fidler, Janice Main, David Muir, Jonathan N. Weber, Alexander J. Frater, Rodney E. Phillips, Oliver G. Pybus, Philip J.R. Goulder, Myra O. McClure, Graham S. Cooke, Paul Klenerman B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat. Commun. 2010, 1(102).
54. Wei, X.; Decker, J. M.; Wang, S.; Hui, H.; Kappes, J. C.; Wu, X.; Salazar-Gonzalez, J. F.; Salazar, M. G.; Kilby, J. M.; Saag, M. S.; Komarova, N. L.; Nowak, M. A.; Hahn, B. H.; Kwong, P. D.; Shaw, G. M., Antibody neutralization and escape by HIV-1. Nature 2003, 422(6929), 307-12. (Pubitemid 36378357)
55. Richman, D. D.; Wrin, T.; Little, S. J.; Petropoulos, C. J., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003, 100(7), 4144-9. (Pubitemid 36418171)
56. Tomaras, G. D.; Yates, N. L.; Liu, P.; Qin, L.; Fouda, G. G.; Chavez, L. L.; Decamp, A. C.; Parks, R. J.; Ashley, V. C.; Lucas, J. T.; Cohen, M.; Eron, J.; Hicks, C. B.; Liao, H. X.; Self, S. G.; Landucci, G.; Forthal, D. N.; Weinhold, K. J.; Keele, B. F.; Hahn, B. H.; Greenberg, M. L.; Morris, L.; Karim, S. S.; Blattner, W. A.; Montefiori, D. C.; Shaw, G. M.; Perelson, A. S.; Haynes, B. F., Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008, 82(24), 12449-63.
57. Lane, H. C.; Masur, H.; Edgar, L. C.; Whalen, G.; Rook, A. H.; Fauci, A. S., Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983, 309(8), 453-8. (Pubitemid 13041485)
58. Opravil, M.; Fierz, W.; Matter, L.; Blaser, J.; Luthy, R., Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991, 84(2), 185-9.
59. Nair, N.; Moss, W. J.; Scott, S.; Mugala, N.; Ndhlovu, Z. M.; Lilo, K.; Ryon, J. J.; Monze, M.; Quinn, T. C.; Cousens, S.; Cutts, F.; Griffin, D. E., HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis 2009, 200(7), 1031-8.
60. Rigaud, M.; Borkowsky, W.; Muresan, P.; Weinberg, A.; Larussa, P.; Fenton, T.; Read, J. S.; Jean-Philippe, P.; Fergusson, E.; Zimmer, B.; Smith, D.; Kraimer, J., Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis 2008, 198(8), 1123-30.
61. He, B.; Qiao, X.; Klasse, P. J.; Chiu, A.; Chadburn, A.; Knowles, D. M.; Moore, J. P.; Cerutti, A., HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006, 176(7), 3931-41. (Pubitemid 44264370)
62. Swingler, S.; Zhou, J.; Swingler, C.; Dauphin, A.; Greenough, T.; Jolicoeur, P.; Stevenson, M., Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe 2008, 4(1), 63-76. (Pubitemid 351958115)
63. Titanji, K.; Chiodi, F.; Bellocco, R.; Schepis, D.; Osorio, L.; Tassandin, C.; Tambussi, G.; Grutzmeier, S.; Lopalco, L.; De Milito, A., Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005, 19(17), 1947-55. (Pubitemid 41669018)
64. De Milito, A.; Morch, C.; Sonnerborg, A.; Chiodi, F., Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001, 15(8), 957-64. (Pubitemid 32476662)
65. De Milito, A.; Nilsson, A.; Titanji, K.; Thorstensson, R.; Reizenstein, E.; Narita, M.; Grutzmeier, S.; Sonnerborg, A.; Chiodi, F., Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004, 103(6), 2180-6. (Pubitemid 38326236)
66. Moir, S.; Malaspina, A.; Ogwaro, K. M.; Donoghue, E. T.; Hallahan, C. W.; Ehler, L. A.; Liu, S.; Adelsberger, J.; Lapointe, R.; Hwu, P.; Baseler, M.; Orenstein, J. M.; Chun, T. W.; Mican, J. A.; Fauci, A. S., HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A 2001, 98(18), 10362-7. (Pubitemid 32803025)
67. Moir, S.; Malaspina, A.; Pickeral, O. K.; Donoghue, E. T.; Vasquez, J.; Miller, N. J.; Krishnan, S. R.; Planta, M. A.; Turney, J. F.; Justement, J. S.; Kottilil, S.; Dybul, M.; Mican, J. M.; Kovacs, C.; Chun, T. W.; Birse, C. E.; Fauci, A. S., Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med 2004, 200(7), 587-99. (Pubitemid 39258308)
68. Malaspina, A.; Moir, S.; Ho, J.; Wang, W.; Howell, M. L.; O'Shea, M. A.; Roby, G. A.; Rehm, C. A.; Mican, J. M.; Chun, T. W.; Fauci, A. S., Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A 2006, 103(7), 2262-7. (Pubitemid 43271658)
69. Moir, S.; Malaspina, A.; Ho, J.; Wang, W.; Dipoto, A. C.; O'Shea, M. A.; Roby, G.; Mican, J. M.; Kottilil, S.; Chun, T. W.; Proschan, M. A.; Fauci, A. S., Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008, 197(4), 572-9. (Pubitemid 351321535)
70. Cagigi, A.; Nilsson, A.; De Milito, A.; Chiodi, F., B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Vaccine 2008, 26(24), 3016-25.
71. van Grevenynghe, J.; Halwani, R.; Chomont, N.; Ancuta, P.; Peretz, Y.; Tanel, A.; Procopio, F. A.; shi, Y.; Said, E. A.; Haddad, E. K.; Sekaly, R. P., Lymph node architecture collapse and consequent modulation of FOXO3a pathway on memory T-and B-cells during HIV infection. Semin Immunol 2008, 20(3), 196-203.
72. Levesque, M. C.; Moody, M. A.; Hwang, K. K.; Marshall, D. J.; Whitesides, J. F.; Amos, J. D.; Gurley, T. C.; Allgood, S.; Haynes, B. B.; Vandergrift, N. A.; Plonk, S.; Parker, D. C.; Cohen, M. S.; Tomaras, G. D.; Goepfert, P. A.; Shaw, G. M.; Schmitz, J. E.; Eron, J. J.; Shaheen, N. J.; Hicks, C. B.; Liao, H. X.; Markowitz, M.; Kelsoe, G.; Margolis, D. M.; Haynes, B. F., Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009, 6(7), e1000107.
73. Pensieroso, S.; Cagigi, A.; Palma, P.; Nilsson, A.; Capponi, C.; Freda, E.; Bernardi, S.; Thorstensson, R.; Chiodi, F.; Rossi, P., Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A 2009, 106(19), 7939-44.
74. Zhu, P.; Liu, J.; Bess, J., Jr.; Chertova, E.; Lifson, J. D.; Grise, H.; Ofek, G. A.; Taylor, K. A.; Roux, K. H., Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441(7095), 847-52.
75. Kwong, P. D.; Doyle, M. L.; Casper, D. J.; Cicala, C.; Leavitt, S. A.; Majeed, S.; Steenbeke, T. D.; Venturi, M.; Chaiken, I.; Fung, M.; Katinger, H.; Parren, P. W.; Robinson, J.; Van Ryk, D.; Wang, L.; Burton, D. R.; Freire, E.; Wyatt, R.; Sodroski, J.; Hendrickson, W. A.; Arthos, J., HIV-1 evades antibody-mediated neutralization through conformational masking of receptorbinding sites. Nature 2002, 420(6916), 678-82. (Pubitemid 36764500)
76. Thali, M.; Moore, J. P.; Furman, C.; Charles, M.; Ho, D. D.; Robinson, J.; Sodroski, J., Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993, 67(7), 3978-88. (Pubitemid 23180722)
77. Frost, S. D.; Wrin, T.; Smith, D. M.; Kosakovsky Pond, S. L.; Liu, Y.; Paxinos, E.; Chappey, C.; Galovich, J.; Beauchaine, J.; Petropoulos, C. J.; Little, S. J.; Richman, D. D., Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 2005, 102(51), 18514-9. (Pubitemid 43011257)
78. Barbas, C. F., 3rd; Bjorling, E.; Chiodi, F.; Dunlop, N.; Cababa, D.; Jones, T. M.; Zebedee, S. L.; Persson, M. A.; Nara, P. L.; Norrby, E.; et al., Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 1992, 89(19), 9339-43.
79. Wu, X.; Yang, Z. Y.; Li, Y.; Hogerkorp, C. M.; Schief, W. R.; Seaman, M. S.; Zhou, T.; Schmidt, S. D.; Wu, L.; Xu, L.; Longo, N. S.; McKee, K.; O'Dell, S.; Louder, M. K.; Wycuff, D. L.; Feng, Y.; Nason, M.; Doria-Rose, N.; Connors, M.; Kwong, P. D.; Roederer, M.; Wyatt, R. T.; Nabel, G. J.; Mascola, J. R., Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(5993), 856-61.
80. Moulard, M.; Phogat, S. K.; Shu, Y.; Labrijn, A. F.; Xiao, X.; Binley, J. M.; Zhang, M. Y.; Sidorov, I. A.; Broder, C. C.; Robinson, J.; Parren, P. W.; Burton, D. R.; Dimitrov, D. S., Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 2002, 99(10), 6913-8. (Pubitemid 34526232)
81. Muster, T.; Steindl, F.; Purtscher, M.; Trkola, A.; Klima, A.; Himmler, G.; Ruker, F.; Katinger, H., A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67(11), 6642-7. (Pubitemid 23309131)
82. Zwick, M. B.; Labrijn, A. F.; Wang, M.; Spenlehauer, C.; Saphire, E. O.; Binley, J. M.; Moore, J. P.; Stiegler, G.; Katinger, H.; Burton, D. R.; Parren, P. W., Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75(22), 10892-905. (Pubitemid 33034579)
83. Scanlan, C. N.; Pantophlet, R.; Wormald, M. R.; Ollmann Saphire, E.; Stanfield, R.; Wilson, I. A.; Katinger, H.; Dwek, R. A.; Rudd, P. M.; Burton, D. R., The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 2002, 76(14), 7306-21.
84. Walker, L. M.; Phogat, S. K.; Chan-Hui, P. Y.; Wagner, D.; Phung, P.; Goss, J. L.; Wrin, T.; Simek, M. D.; Fling, S.; Mitcham, J. L.; Lehrman, J. K.; Priddy, F. H.; Olsen, O. A.; Frey, S. M.; Hammond, P. W.; Kaminsky, S.; Zamb, T.; Moyle, M.; Koff, W. C.; Poignard, P.; Burton, D. R., Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950), 285-9.
85. Pietzsch, J.; Scheid, J. F.; Mouquet, H.; Klein, F.; Seaman, M. S.; Jankovic, M.; Corti, D.; Lanzavecchia, A.; Nussenzweig, M. C., Human anti-HIVneutralizing antibodies frequently target a conserved epitope essential for viral fitness. J Exp Med 2010, 207(9), 1995-2002.
86. Hessell, A. J.; Hangartner, L.; Hunter, M.; Havenith, C. E.; Beurskens, F. J.; Bakker, J. M.; Lanigan, C. M.; Landucci, G.; Forthal, D. N.; Parren, P. W.; Marx, P. A.; Burton, D. R., Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449(7158), 101-4. (Pubitemid 47373775)
87. Forthal, D. N.; Landucci, G.; Phan, T. B.; Becerra, J., Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol 2005, 79(4), 2042-9. (Pubitemid 40204561)
88. Forthal, D. N.; Landucci, G.; Cole, K. S.; Marthas, M.; Becerra, J. C.; Van Rompay, K., Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol 2006, 80(18), 9217-25. (Pubitemid 44359994)
89. Baum, L. L.; Cassutt, K. J.; Knigge, K.; Khattri, R.; Margolick, J.; Rinaldo, C.; Kleeberger, C. A.; Nishanian, P.; Henrard, D. R.; Phair, J., HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996, 157(5), 2168-73. (Pubitemid 126449697)
90. Lambotte, O.; Ferrari, G.; Moog, C.; Yates, N. L.; Liao, H. X.; Parks, R. J.; Hicks, C. B.; Owzar, K.; Tomaras, G. D.; Montefiori, D. C.; Haynes, B. F.; Delfraissy, J. F., Heterogeneous neutralizing antibody and antibodydependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23(8), 897-906.
91. Ng, C. T.; Jaworski, J. P.; Jayaraman, P.; Sutton, W. F.; Delio, P.; Kuller, L.; Anderson, D.; Landucci, G.; Richardson, B. A.; Burton, D. R.; Forthal, D. N.; Haigwood, N. L., Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010, 16(10), 1117-9.
92. Xu, W.; Santini, P. A.; Sullivan, J. S.; He, B.; Shan, M.; Ball, S. C.; Dyer, W. B.; Ketas, T. J.; Chadburn, A.; Cohen-Gould, L.; Knowles, D. M.; Chiu, A.; Sanders, R. W.; Chen, K.; Cerutti, A., HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 2009, 10(9), 1008-17.
93. Qiao, X.; He, B.; Chiu, A.; Knowles, D. M.; Chadburn, A.; Cerutti, A., Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006, 7(3), 302-10.
94. Scheid, J. F.; Mouquet, H.; Feldhahn, N.; Seaman, M. S.; Velinzon, K.; Pietzsch, J.; Ott, R. G.; Anthony, R. M.; Zebroski, H.; Hurley, A.; Phogat, A.; Chakrabarti, B.; Li, Y.; Connors, M.; Pereyra, F.; Walker, B. D.; Wardemann, H.; Ho, D.; Wyatt, R. T.; Mascola, J. R.; Ravetch, J. V.; Nussenzweig, M. C., Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458(7238), 636-40.
95. Gorny, M. K.; Wang, X. H.; Williams, C.; Volsky, B.; Revesz, K.; Witover, B.; Burda, S.; Urbanski, M.; Nyambi, P.; Krachmarov, C.; Pinter, A.; Zolla-Pazner, S.; Nadas, A., Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol Immunol 2009, 46(5), 917-26.
96. Huang, C. C.; Venturi, M.; Majeed, S.; Moore, M. J.; Phogat, S.; Zhang, M. Y.; Dimitrov, D. S.; Hendrickson, W. A.; Robinson, J.; Sodroski, J.; Wyatt, R.; Choe, H.; Farzan, M.; Kwong, P. D., Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptorbinding site on gp120. Proc Natl Acad Sci U S A 2004, 101(9), 2706-11. (Pubitemid
97. Berberian, L.; Goodglick, L.; Kipps, T. J.; Braun, J., Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 1993, 261(5128), 1588-91. (Pubitemid 23319603)
98. Scamurra, R. W.; Miller, D. J.; Dahl, L.; Abrahamsen, M.; Kapur, V.; Wahl, S. M.; Milner, E. C.; Janoff, E. N., Impact of HIV-1 infection on VH3 gene repertoire of naive human B cells. J Immunol 2000, 164(10), 5482-91. (Pubitemid 30305233)
99. Scamurra, R. W.; Nelson, D. B.; Lin, X. M.; Miller, D. J.; Silverman, G. J.; Kappel, T.; Thurn, J. R.; Lorenz, E.; Kulkarni-Narla, A.; Janoff, E. N., Mucosal plasma cell repertoire during HIV-1 infection. J Immunol 2002, 169(7), 4008-16.
100. Pejchal, R.; Walker, L. M.; Stanfield, R. L.; Phogat, S. K.; Koff, W. C.; Poignard, P.; Burton, D. R.; Wilson, I. A., Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107(25), 11483-8.
101. Haynes, B. F.; Fleming, J.; St Clair, E. W.; Katinger, H.; Stiegler, G.; Kunert, R.; Robinson, J.; Scearce, R. M.; Plonk, K.; Staats, H. F.; Ortel, T. L.; Liao, H. X.; Alam, S. M., Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308(5730), 1906-8. (Pubitemid 40941873)
102. Verkoczy, L.; Diaz, M.; Holl, T. M.; Ouyang, Y. B.; Bouton-Verville, H.; Alam, S. M.; Liao, H. X.; Kelsoe, G.; Haynes, B. F., Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A 107(1), 181-6.
103. Mouquet, H.; Scheid, J. F.; Zoller, M. J.; Krogsgaard, M.; Ott, R. G.; Shukair, S.; Artyomov, M. N.; Pietzsch, J.; Connors, M.; Pereyra, F.; Walker, B. D.; Ho, D. D.; Wilson, P. C.; Seaman, M. S.; Eisen, H. N.; Chakraborty, A. K.; Hope, T. J.; Ravetch, J. V.; Wardemann, H.; Nussenzweig, M. C., Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467(7315), 591-5.
104. Raux, M.; Finkielsztejn, L.; Salmon-Ceron, D.; Bouchez, H.; Excler, J. L.; Dulioust, E.; Grouin, J. M.; Sicard, D.; Blondeau, C., Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses 1999, 15(15), 1365-76. (Pubitemid 29480746)
105. Raux, M.; Finkielsztejn, L.; Salmon-Ceron, D.; Bouchez, H.; Excler, J. L.; Dulioust, E.; Grouin, J. M.; Sicard, D.; Blondeau, C., IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses 2000, 16(6), 583-94. (Pubitemid 30210956)
106. Bomsel, M.; Heyman, M.; Hocini, H.; Lagaye, S.; Belec, L.; Dupont, C.; Desgranges, C., Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998, 9(2), 277-87. (Pubitemid 28400041)
107. Wolbank, S.; Kunert, R.; Stiegler, G.; Katinger, H., Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) antihuman immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol 2003, 77(7), 4095-103. (Pubitemid 36350949)
108. Sheppard, N. C.; Bates, A. C.; Sattentau, Q. J., A functional human IgM response to HIV-1 Env after immunization with NYVAC HIV C. AIDS 2007, 21(4), 524-7.
109. Cerutti, A.; Chen, K.; Chorny, A., Immunoglobulin Responses at the Mucosal Interfaces. Annu Rev Immunol. 2011, 29, 273-93.
110. Mestecky, J.; Jackson, S.; Moldoveanu, Z.; Nesbit, L. R.; Kulhavy, R.; Prince, S. J.; Sabbaj, S.; Mulligan, M. J.; Goepfert, P. A., Paucity of antigenspecific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004, 20(9), 972-88. (Pubitemid 39369704)
111. Kaul, R.; Plummer, F.; Clerici, M.; Bomsel, M.; Lopalco, L.; Broliden, K., Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 2001, 15(3), 431-2. (Pubitemid 32163839)
112. Kaul, R.; Trabattoni, D.; Bwayo, J. J.; Arienti, D.; Zagliani, A.; Mwangi, F. M.; Kariuki, C.; Ngugi, E. N.; MacDonald, K. S.; Ball, T. B.; Clerici, M.; Plummer, F. A., HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999, 13(1), 23-9. (Pubitemid 29078060)
113. Mazzoli, S.; Trabattoni, D.; Lo Caputo, S.; Piconi, S.; Ble, C.; Meacci, F.; Ruzzante, S.; Salvi, A.; Semplici, F.; Longhi, R.; Fusi, M. L.; Tofani, N.; Biasin, M.; Villa, M. L.; Mazzotta, F.; Clerici, M., HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997, 3(11), 1250-7. (Pubitemid 27508826)
114. Devito, C.; Broliden, K.; Kaul, R.; Svensson, L.; Johansen, K.; Kiama, P.; Kimani, J.; Lopalco, L.; Piconi, S.; Bwayo, J. J.; Plummer, F.; Clerici, M.; Hinkula, J., Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000, 165(9), 5170-6.
115. Hirbod, T.; Kaul, R.; Reichard, C.; Kimani, J.; Ngugi, E.; Bwayo, J. J.; Nagelkerke, N.; Hasselrot, K.; Li, B.; Moses, S.; MacDonald, K. S.; Broliden, K., HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008, 22(6), 727-35. (Pubitemid 351450641)
116. Belec, L.; Ghys, P. D.; Hocini, H.; Nkengasong, J. N.; Tranchot-Diallo, J.; Diallo, M. O.; Ettiegne-Traore, V.; Maurice, C.; Becquart, P.; Matta, M.; Si-Mohamed, A.; Chomont, N.; Coulibaly, I. M.; Wiktor, S. Z.; Kazatchkine, M. D., Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis 2001, 184(11), 1412-22. (Pubitemid 33108855)
117. Tudor, D.; Derrien, M.; Diomede, L.; Drillet, A. S.; Houimel, M.; Moog, C.; Reynes, J. M.; Lopalco, L.; Bomsel, M., HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009, 2(5), 412-26.
118. Dorrell, L.; Hessell, A. J.; Wang, M.; Whittle, H.; Sabally, S.; Rowland-Jones, S.; Burton, D. R.; Parren, P. W., Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 2000, 14(9), 1117-22. (Pubitemid 30420654)
119. Horton, R. E.; Ball, T. B.; Wachichi, C.; Jaoko, W.; Rutherford, W. J.; McKinnon, L.; Kaul, R.; Rebbapragada, A.; Kimani, J.; Plummer, F. A., Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res Hum Retroviruses 2009, 25(1), 83-92.
120. Veazey, R. S.; Shattock, R. J.; Pope, M.; Kirijan, J. C.; Jones, J.; Hu, Q.; Ketas, T.; Marx, P. A.; Klasse, P. J.; Burton, D. R.; Moore, J. P., Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003, 9(3), 343-6. (Pubitemid 36362791)
121. Stamatatos, L.; Morris, L.; Burton, D. R.; Mascola, J. R., Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009, 15(8), 866-70.
122. Haase, A. T., Early Events in Sexual Transmission of HIV and SIV and Opportunities for Interventions. Annu Rev Med 2011, 62, 127-39.